|
|
|
|
|
|
|
|
Journal of Ovarian Research | open access - CA-125--indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
Background
There is no consensus regarding the management of ovarian cancer patients, who have
shown complete clinical response (CCR) to primary therapy and have rising cancer antigen
CA-125 levels but have no symptoms of recurrent disease. The present study aims to
determine whether follow-up CA-125 levels can be used to identify the need for imaging
studies and secondary cytoreductive surgery (CRS).
Conclusions
The increase of serum CA-125 levels is an early warning of clinical relapse in ovarian
cancer. Using CA-125 levels in guiding the treatment of patients with asymptomatic
recurrent ovarian cancer, who have shown CCR to primary therapy, can facilitate optimal
secondary CRS and extend the survival duration of the patients.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.